Trends, market analysis, and market growth reports on pharmaceutical ingredient suppliers and manufacturers. Sourcing and supply of active pharmaceutical ingredients (APIs), intermediates, excipients.
July 29, 2010 ePT--the Electronic Newsletter of Pharmaceutical Technology
Merck and Sinopharm Sign Agreement; Agilent Appoints CFO; And More.
 |
July 28, 2010
View companies' outsourcing profiles from PharmTech's 2010 Outsourcing Resources Fast Locator Index in the following categories.
 |
July 28, 2010
Companies' outsourcing profiles from PharmTech's 2010 Outsourcing Resources Fast Locator Index.
 |
July 22, 2010 By:Patricia Van Arnum ePT--the Electronic Newsletter of Pharmaceutical Technology
The Society of Chemical Manufacturers and Affiliates (SOCMA) expressed "strong concern" over legislation introduced in the US Senate earlier this month regarding chemical-site security.
 |
July 22, 2010 By:Erik Greb ePT--the Electronic Newsletter of Pharmaceutical Technology
Merck KGaA (Darmstadt, Germany), a global pharmaceutical and chemical company, completed its acquisition of Millipore (Billerica, MA), a life-science company, last Thursday for an aggregate purchase price of roughly EUR 5.2 billion ($6.7 billion).
 |
July 22, 2010 ePT--the Electronic Newsletter of Pharmaceutical Technology
Pfizer Ends Second Tanezumab Clinical Program; Catalent VP Joins USP Panel; And More.
 |
July 21, 2010 By:Carrie Shipley, Susan Freers
Using pregelatinized starch as the absorbent diluent in the Moisture Activated Dry Granulation (MADG) process, combinations of maltodextrin and povidone were tested to determine optimum binder level.
 |
July 15, 2010 ePT--the Electronic Newsletter of Pharmaceutical Technology
Xcelience and Penn Form Joint Venture; Almac Appoints QA Director; And More.
 |
July 8, 2010 By:Patricia Van Arnum ePT--the Electronic Newsletter of Pharmaceutical Technology
The US House of Representatives passed on July 1, 2010, HR 4899, the Supplemental Appropriations Act of 2010, which included provisions restricting patent settlements between innovator-drug and generic-drug companies, a move that drew criticism from both sectors of the pharmaceutical industry.
 |
|